Last reviewed · How we verify
Malignant melanoma
Approved treatments
- Intron A · Merck & Co.
- Vindesin · The Lymphoma Academic Research Organisation
- Eldisine
- Imlygic · Johns Hopkins University
- Imlygic · Amgen
Imlygic is a genetically modified virus that selectively infects and kills cancer cells, stimulating an anti-tumor immune response. - Hydroxycarbamide · University of Birmingham
- Siklos · Theravia
- Xromi · Nova Laboratories Limited
- Hydroxycarbamid · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Malignant melanoma patent landscape — cliff calendar, originator estates, attackable patents
- Malignant melanoma treatment landscape brief
- Malignant melanoma treatment updates RSS
Frequently asked questions about Malignant melanoma
What drugs treat Malignant melanoma?
Tracked treatments include Intron A, Vindesin, Eldisine, Imlygic, Hydroxycarbamide, Siklos, Xromi, Hydroxycarbamid.
What is the treatment for Malignant melanoma?
Standard treatment for Malignant melanoma includes Intron A, Vindesin, Eldisine, Imlygic, Hydroxycarbamide. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Malignant melanoma patent cliff · Malignant melanoma CI report
- Treatment: Intron A · Merck & Co.
- Treatment: Vindesin · The Lymphoma Academic Research Organisation
- Treatment: Eldisine
- Treatment: Imlygic · Johns Hopkins University
- Treatment: Imlygic · Amgen
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing